



Complete Summary

TITLE

Lipid management in adults: percentage of patients on a lipid lowering medication who have a fasting lipid panel every 3 to 12 months.

SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Lipid management in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2007 Jun. 77 p. [128 references]

Measure Domain

PRIMARY MEASURE DOMAIN

Process

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the [Measure Validity](#) page.

SECONDARY MEASURE DOMAIN

Does not apply to this measure

Brief Abstract

DESCRIPTION

This measure is used to assess the percentage of patients on a lipid-lowering medication who have a fasting lipid panel every 3 to 12 months.

RATIONALE

The priority aim addressed by this measure is to improve the percentage of patients on lipid-lowering medication who receive regular follow-up care for lipid disorder.

PRIMARY CLINICAL COMPONENT

Dyslipidemia; lipid-lowering medication (bile acid sequestrant [BAS], fibric acids, niacin, statin); fasting lipid panel (total cholesterol, high-density lipoprotein

[HDL]-cholesterol, triglycerides, and calculated low-density lipoprotein [LDL]-cholesterol)

DENOMINATOR DESCRIPTION

Total number of patients who are on lipid-lowering medication whose records are reviewed (see the related "Denominator Inclusions/Exclusions" field in the Complete Summary)

NUMERATOR DESCRIPTION

Number of patients on lipid-lowering medication who have a fasting lipid panel (see the related "Numerator Inclusions/Exclusions" field in the Complete Summary)

Evidence Supporting the Measure

EVIDENCE SUPPORTING THE CRITERION OF QUALITY

- A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

NATIONAL GUIDELINE CLEARINGHOUSE LINK

- [Lipid management in adults.](#)

Evidence Supporting Need for the Measure

NEED FOR THE MEASURE

Unspecified

State of Use of the Measure

STATE OF USE

Current routine use

CURRENT USE

Internal quality improvement

Application of Measure in its Current Use

CARE SETTING

Physician Group Practices/Clinics

PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Physicians

LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED

Group Clinical Practices

TARGET POPULATION AGE

Age 20 to 75 years

TARGET POPULATION GENDER

Either male or female

STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

Characteristics of the Primary Clinical Component

INCIDENCE/PREVALENCE

Unspecified

ASSOCIATION WITH VULNERABLE POPULATIONS

Unspecified

BURDEN OF ILLNESS

Unspecified

UTILIZATION

Unspecified

COSTS

Unspecified

Institute of Medicine National Healthcare Quality Report Categories

IOM CARE NEED

Living with Illness

IOM DOMAIN

Effectiveness

Data Collection for the Measure

CASE FINDING

Users of care only

DESCRIPTION OF CASE FINDING

All patients age 20 to 75 who are dyslipidemic and on a lipid-lowering medication

The preferred way to collect these data:

- Patients 20 to 75 years old who are dyslipidemic and on a lipid-lowering medication could be identified. This would include patients with hypercholesterolemia (high low-density lipoprotein [LDL], normal triglycerides and high-density lipoprotein [HDL]), combined hyperlipidemia (high LDL and triglycerides), hypertriglyceridemia and hypercholesterolemia (with isolated low HDL) who are on a lipid-lowering medication.
- Each medical group would select at random 20 patients for measurement each month to determine if a fasting lipid panel has been done in the past 3 to 12 months.

Data on 20 patients are collected monthly and reported quarterly.

DENOMINATOR SAMPLING FRAME

Patients associated with provider

DENOMINATOR INCLUSIONS/EXCLUSIONS

Inclusions

Total number of patients who are on lipid-lowering medication* whose records are reviewed

*Patients age 20 to 75 years old who are dyslipidemic on a lipid-lowering medication**, including: bile acid sequestrant (BAS), fibric acids, niacin, statin.

**Refer to Appendix C, "Drug Companion Document - Treatment Options for Dyslipidemia" in the original measure documentation for a complete listing of lipid-lowering medications.

Exclusions

Unspecified

RELATIONSHIP OF DENOMINATOR TO NUMERATOR

All cases in the denominator are equally eligible to appear in the numerator

DENOMINATOR (INDEX) EVENT

Clinical Condition
Therapeutic Intervention

DENOMINATOR TIME WINDOW

Time window precedes index event

NUMERATOR INCLUSIONS/EXCLUSIONS

Inclusions

Number of patients on lipid-lowering medication who have a fasting lipid panel*

*Of the patients in the denominator, those who have had a fasting lipid panel in the past 3 to 12 months (measurement of total cholesterol, high-density lipoprotein [HDL]-cholesterol, triglycerides and calculated low-density lipoprotein [LDL]-cholesterol after a 12-hour fasting period).

Exclusions

Unspecified

MEASURE RESULTS UNDER CONTROL OF HEALTH CARE PROFESSIONALS, ORGANIZATIONS AND/OR POLICYMAKERS

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

NUMERATOR TIME WINDOW

Fixed time period

DATA SOURCE

Administrative data
Medical record

LEVEL OF DETERMINATION OF QUALITY

Individual Case

PRE-EXISTING INSTRUMENT USED

Unspecified

Computation of the Measure

SCORING

Rate

INTERPRETATION OF SCORE

Better quality is associated with a higher score

ALLOWANCE FOR PATIENT FACTORS

Unspecified

STANDARD OF COMPARISON

Internal time comparison

Evaluation of Measure Properties**EXTENT OF MEASURE TESTING**

Unspecified

Identifying Information**ORIGINAL TITLE**

Percentage of patients on a lipid-lowering medication who have a fasting lipid panel every 3 to 12 months.

MEASURE COLLECTION

[Lipid Management in Adults Measures](#)

DEVELOPER

Institute for Clinical Systems Improvement

ADAPTATION

Measure was not adapted from another source.

RELEASE DATE

2003 Jul

REVISION DATE

2007 Jun

MEASURE STATUS

This is the current release of the measure.

This measure updates a previous version: Institute for Clinical Systems Improvement (ICSI). Lipid management in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2006 Jun. 76 p.

SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Lipid management in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2007 Jun. 77 p. [128 references]

MEASURE AVAILABILITY

The individual measure, "Percentage of patients on a lipid lowering medication who have a fasting lipid panel every 3 to 12 months," is published in "Health Care Guideline: Lipid Management in Adults." This document is available from the [Institute for Clinical Systems Improvement \(ICSI\) Web site](#).

For more information, contact ICSI at, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; phone: 952-814-7060; fax: 952-858-9675; Web site: www.icsi.org; e-mail: icsi.info@icsi.org.

NQMC STATUS

This NQMC summary was completed by ECRI on April 28, 2004. This NQMC summary was updated by ECRI Institute on June 9, 2005, August 21, 2005, August 4, 2006 and again on October 1, 2007.

COPYRIGHT STATEMENT

This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions.

The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures.

Disclaimer

NQMC DISCLAIMER

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at <http://www.qualitymeasures.ahrq.gov/about/inclusion.aspx>.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. The inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.

© 2008 National Quality Measures Clearinghouse

Date Modified: 11/3/2008

